Systemic medications and their impact on age-related macular degeneration development and progression: a review of current evidence
Multiple systemic medications have highlighted mixed or stage-dependent benefits on AMD development and progression. Some agents such as metformin and aspirin have shown conflicting findings, having been evaluated in randomized trials and large observational studies. Other medications including GLP-1 agonists, dopamine agonists, statins, fenofibrates, and danicopan show early promise in more limited studies, but require further clinical validation.
Authors
- Amer F. Alsoudi (ORCID: https://orcid.org/0000-0002-2492-1993)
- Ehsan Rahimy (ORCID: https://orcid.org/0000-0001-8446-7078)
- Melissa Yuan (ORCID: https://orcid.org/0000-0002-5097-110X)
- Ahmed Alshaikhsalama (ORCID: https://orcid.org/0000-0001-9465-8994)
Institutions
- Associated Retinal Consultants (US)
- Palo Alto Institute (US)
- Smith-Kettlewell Eye Research Institute (US)
- The University of Texas Southwestern Medical Center (US)
- Stanford University (US)
Publication Details
- Journal
- Current Opinion in Ophthalmology
- Published
- 2025-11-27
- DOI
- https://doi.org/10.1097/icu.0000000000001198
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00